SKOV-3 cell imaging by paramagnetic particles labeled with hairpin cell-penetrating peptides

Chinese Medical Journal

Volumn 124, Issue 1, 2011, Pages 111-117

  Zhai, Xiao Hui ^a   Liu, Min ^b   Guo, Xiao Juan ^b   Wang, Si Cen ^a   Zhang, Hong Xia ^b   Guo, You Min ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cell penetrating peptides; Magnetic resonance imaging; Matrix metalloproteinase 2; Molecular imaging

Indexed keywords

CELL PENETRATING PEPTIDE; FLUORESCEIN ISOTHIOCYANATE; GADOTERIC ACID; GELATINASE A; HAIRPIN CELL PENETRATING PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY TEST; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INTERNALIZATION; MOLECULAR IMAGING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY ADENOCARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOLID PHASE SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; ZYMOGRAPHY;

CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE 2; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANOMETALLIC COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78651250321     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.01.021     Document Type: Article

References (21)

1. Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-289.
2. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000; 97: 3884-3889.
3. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocar-cinoma. Anticancer Res 2005; 25: 4101-4105.
4. Wiegand S, Dunne AA, Muller HH, Mandic R, Barth P, Davis RK, et al. Meta analysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 2005; 104: 94-100.
5. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001; 221: 523-529.
6. Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol 2004; 31: 337-344.
7. Heckl S, Pipkorn R, Waldeck W, Spring H, Jenne J, von der Lieth CW, et al. Intracelluar visualization of prostate cancer using magnetic resonance imaging. Cancer Res 2003; 63: 4766-4772.
8. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001; 219: 316-333.
9. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 2005; 57: 529-545.
10. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 2007; 24: 1977-1992.
11. Benjamin IF, Stefanie JM, Zurab S, Paul W, Christopber HC. Breaching biological barriers: Protein translocation domains as tools for molecular imaging and therapy. Mol Imaging 2003; 2: 313-323.
12. Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM. I labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1/Cip-1. Eur J Nucl Med Mol Imaging 2007; 4: 368-377.
13. Jain M, Venkatraman G, Batra SK. Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy. Eur J Nucl Med Mol Imaging 2007; 34: 973-977.
14. Tao J, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004; 101: 17867-17872.
15. Prantner AM, Sharma V, Garbow JR, Piwnica-Worms D. Synthesis and characterization of a Gd-DOTA-Permeation peptide for magnetic resonance relaxation enhancement of intracellular targets. Mol Imaging 2003; 2: 333-342.
16. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003; 63: 6537-6542.
17. Johansson N, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000; 57: 5-15.
18. Arbab AS, Liu W, Frank JA. Cellular magnetic resonance imaging: current status and future prospects. Expert Rev Med Devices 2006; 3: 427-439.
19. Ming Z, Moritz FK, Josephson, L, Weissleder R. Differential conjugation of Tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002; 13: 840-844.
20. Guo YM, Liu M, Yang JL, Guo XJ, Wang SC, Duan XY, et al. Intercellular imaging by a polyarginine derived cell penetrating peptide labeled magnetic resonance contrast agent, diethylenetriamine pentaacetic acid gadolinium. Chin Med J 2007; 120: 50-55.
21. Liu M, Guo YM, Wu QF, Yang JL, Wang P, Wang SC, et al. Paramagnetic particles carried by cell-penetrating peptide tracking of bone marrow mesenchymal stem cells, a research in vitro. Biochem Biophys Res Commun 2006; 347: 133-140.